Download MendeleyA bispecific inhibitor of complement and coagulation blocks activation in complementopathy models via a novel mechanism.
Andersen, J.F., Lei, H., Strayer, E.C., Kanai, T., Pham, V., Pan, X.Z., Alvarenga, P.H., Gerber, G.F., Asojo, O.A., Francischetti, I.M.B., Brodsky, R.A., Valenzuela, J.G., Ribeiro, J.M.C.(2023) Blood 141: 3109-3121
- PubMed: 36947859 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1182/blood.2022019359
- Primary Citation Related Structures:
8ENU, 8EO2, 8EOK - PubMed Abstract:
Inhibitors of complement and coagulation are present in the saliva of a variety of blood-feeding arthropods that transmit parasitic and viral pathogens. Here, we describe the structure and mechanism of action of the sand fly salivary protein lufaxin, which inhibits the formation of the central alternative C3 convertase (C3bBb) and inhibits coagulation factor Xa (fXa). Surface plasmon resonance experiments show that lufaxin stabilizes the binding of serine protease factor B (FB) to C3b but does not detectably bind either C3b or FB alone. The crystal structure of the inhibitor reveals a novel all β-sheet fold containing 2 domains. A structure of the lufaxin-C3bB complex obtained via cryo-electron microscopy (EM) shows that lufaxin binds via its N-terminal domain at an interface containing elements of both C3b and FB. By occupying this spot, the inhibitor locks FB into a closed conformation in which proteolytic activation of FB by FD cannot occur. C3bB-bound lufaxin binds fXa at a separate site in its C-terminal domain. In the cryo-EM structure of a C3bB-lufaxin-fXa complex, the inhibitor binds to both targets simultaneously, and lufaxin inhibits fXa through substrate-like binding of a C-terminal peptide at the active site as well as other interactions in this region. Lufaxin inhibits complement activation in ex vivo models of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH) as well as thrombin generation in plasma, providing a rationale for the development of a bispecific inhibitor to treat complement-related diseases in which thrombosis is a prominent manifestation.
- Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD.
Organizational Affiliation:
